Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2004 Nov;59(11):960–965. doi: 10.1136/thx.2003.017756

Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome

R Menendez 1, A Torres 1, R Zalacain 1, J Aspa 1, V Martin 1, L Borderias 1, M Benitez 1, J Ruiz-Manzano 1, d Rodriguez 1, J Blanquer 1, D Perez 1, C Puzo 1, G Sanchez 1, J Gallardo 1, C Alvarez 1, L Molinos 1
PMCID: PMC1746855  PMID: 15516472

Abstract

Background: An inadequate response to initial empirical treatment of community acquired pneumonia (CAP) represents a challenge for clinicians and requires early identification and intervention. A study was undertaken to quantify the incidence of failure of empirical treatment in CAP, to identify risk factors for treatment failure, and to determine the implications of treatment failure on the outcome.

Methods: A prospective multicentre cohort study was performed in 1424 hospitalised patients from 15 hospitals. Early treatment failure (<72 hours), late treatment failure, and in-hospital mortality were recorded.

Results: Treatment failure occurred in 215 patients (15.1%): 134 early failure (62.3%) and 81 late failure (37.7%). The causes were infectious in 86 patients (40%), non-infectious in 34 (15.8%), and undetermined in 95. The independent risk factors associated with treatment failure in a stepwise logistic regression analysis were liver disease, pneumonia risk class, leucopenia, multilobar CAP, pleural effusion, and radiological signs of cavitation. Independent factors associated with a lower risk of treatment failure were influenza vaccination, initial treatment with fluoroquinolones, and chronic obstructive pulmonary disease (COPD). Mortality was significantly higher in patients with treatment failure (25% v 2%). Failure of empirical treatment increased the mortality of CAP 11-fold after adjustment for risk class.

Conclusions: Although these findings need to be confirmed by randomised studies, they suggest possible interventions to decrease mortality due to CAP.

Full Text

The Full Text of this article is available as a PDF (92.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996 May;22(5):387–394. doi: 10.1007/BF01712153. [DOI] [PubMed] [Google Scholar]
  2. Arancibia F., Ewig S., Martinez J. A., Ruiz M., Bauer T., Marcos M. A., Mensa J., Torres A. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med. 2000 Jul;162(1):154–160. doi: 10.1164/ajrccm.162.1.9907023. [DOI] [PubMed] [Google Scholar]
  3. Armstrong G. L., Conn L. A., Pinner R. W. Trends in infectious disease mortality in the United States during the 20th century. JAMA. 1999 Jan 6;281(1):61–66. doi: 10.1001/jama.281.1.61. [DOI] [PubMed] [Google Scholar]
  4. Celedón Juan C., Lange Christoph, Raby Benjamin A., Litonjua Augusto A., Palmer Lyle J., DeMeo Dawn L., Reilly John J., Kwiatkowski David J., Chapman Harold A., Laird Nan. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet. 2004 Jun 2;13(15):1649–1656. doi: 10.1093/hmg/ddh171. [DOI] [PubMed] [Google Scholar]
  5. Dean N. C., Silver M. P., Bateman K. A., James B., Hadlock C. J., Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med. 2001 Apr 15;110(6):451–457. doi: 10.1016/s0002-9343(00)00744-0. [DOI] [PubMed] [Google Scholar]
  6. Dudas V., Hopefl A., Jacobs R., Guglielmo B. J. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 2000 Apr;34(4):446–452. doi: 10.1345/aph.19174. [DOI] [PubMed] [Google Scholar]
  7. Feagan B. G., Marrie T. J., Lau C. Y., Wheeler S. L., Wong C. J., Vandervoort M. K. Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. CMAJ. 2000 May 16;162(10):1415–1420. [PMC free article] [PubMed] [Google Scholar]
  8. Finch R., Schürmann D., Collins O., Kubin R., McGivern J., Bobbaers H., Izquierdo J. L., Nikolaides P., Ogundare F., Raz R. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. 2002 Jun;46(6):1746–1754. doi: 10.1128/AAC.46.6.1746-1754.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fine M. J., Auble T. E., Yealy D. M., Hanusa B. H., Weissfeld L. A., Singer D. E., Coley C. M., Marrie T. J., Kapoor W. N. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243–250. doi: 10.1056/NEJM199701233360402. [DOI] [PubMed] [Google Scholar]
  10. Frías J., Gomis M., Prieto J., Mensa J., Bouza E., García-Rodríguez J. A., Torres A., Dorca J., Zalacaín R., García de Lomas J. Tratemiento antibiótico empírico inicial de la neumonía adquirida en la comunidad. Rev Esp Quimioter. 1998 Sep;11(3):255–261. [PubMed] [Google Scholar]
  11. Gleason P. P., Meehan T. P., Fine J. M., Galusha D. H., Fine M. J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999 Nov 22;159(21):2562–2572. doi: 10.1001/archinte.159.21.2562. [DOI] [PubMed] [Google Scholar]
  12. Gross P. A., Hermogenes A. W., Sacks H. S., Lau J., Levandowski R. A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995 Oct 1;123(7):518–527. doi: 10.7326/0003-4819-123-7-199510010-00008. [DOI] [PubMed] [Google Scholar]
  13. Guest J. F., Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J. 1997 Jul;10(7):1530–1534. doi: 10.1183/09031936.97.10071530. [DOI] [PubMed] [Google Scholar]
  14. Kays Michael B., Smith David W., Wack Matthew E., Denys Gerald A. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy. 2002 Mar;22(3):395–399. doi: 10.1592/phco.22.5.395.33185. [DOI] [PubMed] [Google Scholar]
  15. Kolling U. K., Hansen F., Braun J., Rink L., Katus H. A., Dalhoff K. Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax. 2001 Feb;56(2):121–125. doi: 10.1136/thorax.56.2.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kuru T., Lynch J. P., 3rd Nonresolving or slowly resolving pneumonia. Clin Chest Med. 1999 Sep;20(3):623–651. doi: 10.1016/s0272-5231(05)70241-0. [DOI] [PubMed] [Google Scholar]
  17. Lave J. R., Fine M. J., Sankey S. S., Hanusa B. H., Weissfeld L. A., Kapoor W. N. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. J Gen Intern Med. 1996 Jul;11(7):415–421. doi: 10.1007/BF02600189. [DOI] [PubMed] [Google Scholar]
  18. Marras T. K., Chan C. K. Use of guidelines in treating community-acquired pneumonia. Chest. 1998 Jun;113(6):1689–1694. doi: 10.1378/chest.113.6.1689. [DOI] [PubMed] [Google Scholar]
  19. Menéndez R., Ferrando D., Vallés J. M., Martínez E., Perpiñ M. Initial risk class and length of hospital stay in community-acquired pneumonia. Eur Respir J. 2001 Jul;18(1):151–156. doi: 10.1183/09031936.01.00090001. [DOI] [PubMed] [Google Scholar]
  20. Menéndez Rosario, Ferrando David, Vallés José M., Vallterra Julia. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest. 2002 Aug;122(2):612–617. doi: 10.1378/chest.122.2.612. [DOI] [PubMed] [Google Scholar]
  21. Metersky M. L., Tate J. P., Fine M. J., Petrillo M. K., Meehan T. P. Temporal trends in outcomes of older patients with pneumonia. Arch Intern Med. 2000 Dec 11;160(22):3385–3391. doi: 10.1001/archinte.160.22.3385. [DOI] [PubMed] [Google Scholar]
  22. Minino A. M., Smith B. L. Deaths: preliminary data for 2000. Natl Vital Stat Rep. 2001 Oct 9;49(12):1–40. [PubMed] [Google Scholar]
  23. Montravers P., Fagon J. Y., Chastre J., Lecso M., Dombret M. C., Trouillet J. L., Gibert C. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis. 1993 Jan;147(1):38–44. doi: 10.1164/ajrccm/147.1.38. [DOI] [PubMed] [Google Scholar]
  24. Montón C., Torres A., El-Ebiary M., Filella X., Xaubet A., de la Bellacasa J. P. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med. 1999 Sep;27(9):1745–1753. doi: 10.1097/00003246-199909000-00008. [DOI] [PubMed] [Google Scholar]
  25. Niederman M. S., Mandell L. A., Anzueto A., Bass J. B., Broughton W. A., Campbell G. D., Dean N., File T., Fine M. J., Gross P. A. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001 Jun;163(7):1730–1754. doi: 10.1164/ajrccm.163.7.at1010. [DOI] [PubMed] [Google Scholar]
  26. Niederman M. S., McCombs J. S., Unger A. N., Kumar A., Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998 Jul-Aug;20(4):820–837. doi: 10.1016/s0149-2918(98)80144-6. [DOI] [PubMed] [Google Scholar]
  27. Ortqvist A., Kalin M., Lejdeborn L., Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest. 1990 Mar;97(3):576–582. doi: 10.1378/chest.97.3.576. [DOI] [PubMed] [Google Scholar]
  28. Rosenthal G. E., Harper D. L., Quinn L. M., Cooper G. S. Severity-adjusted mortality and length of stay in teaching and nonteaching hospitals. Results of a regional study. JAMA. 1997 Aug 13;278(6):485–490. [PubMed] [Google Scholar]
  29. Skerrett S. J., Park D. R. Anti-inflammatory treatment of acute and chronic pneumonia. Semin Respir Infect. 2001 Mar;16(1):76–84. doi: 10.1053/srin.2001.22731. [DOI] [PubMed] [Google Scholar]
  30. Torres A., Dorca J., Zalacaín R., Bello S., El-Ebiary M., Molinos L., Arévalo M., Blanquer J., Celis R., Iriberri M. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med. 1996 Nov;154(5):1456–1461. doi: 10.1164/ajrccm.154.5.8912764. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Web extra]
thorax_59_11_960__index.html (1.1KB, html)
thorax_59_11_960__1.pdf (39.9KB, pdf)

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES